← All indications
Leukemia, Hairy Cell
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of hairy or flagellated cells in the blood and bone marrow.
Drugs by status
Approved for this indication (5)
Phase 2 trials (48)
- acalabrutinib
- venetoclax
- bendamustine
- binimetinib
- bl22
- brentuximab vedotin
- busulfan
- bvd-523
- lenalidomide
- prednisone
- doxorubicin
- encorafenib
- entospletinib
- obinutuzumab
- tacrolimus
- naltrexone
- beclomethasone
- pembrolizumab
- anti-tac(fv)-pe38
- Flotetuzumab
- msk-2206
- vincristine
- ibrutinib
- ipilimumab
- sunitinib
- allogeneic hematopoietic stem cells
- vemurafenib
- cyclosporine
- mycophenolate
- cyclophosphamide
- +18 more
Phase 1 trials (28)
- azacitidine
- dexrazoxane
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- diphenhydramine
- devimistat
- ibuprofen
- selinexor
- imatinib
- in111 anti-cd45 monoclonal antibody bc8
- alisertib
- morab-004
- acetaminophen
- bevacizumab
- dasatinib
- tetanus-cmv fusion peptide vaccine
- y90 anti-cd45 monoclonal antibody bc8
- cd22 car-t cells
- cediranib
- oxaliplatin
- obatoclax
- rigosertib
- ranitidine
- dexamethasone
- alvocidib
- choline
- lp-168
- mgd024
- bdtx-4933
Organizations
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (29)
- Seattle Genetics
- Genentech
- Plexxikon
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Cornell University
- Harvard University
- University of Washington
- Northwell Health
- Northwestern University
- Ohio State University
- Oregon Health and Science University
- Rutgers University
- Stanford University
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Michigan
- Yale University
- Mayo Clinic
- University of Chicago
- University of Utah
- City of Hope National Medical Center
- University of Texas at Houston
- Scripps
- State University of New York, Buffalo
- Klinik Hirslanden, Zurich
- American Cancer Society, Inc.
- Memorial Sloan-Kettering Cancer Center
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (2)